Claritas HealthTech’s Subsidiary ISC to Lead Global Deployment of AI Diagnostic Tool for Bladder Cancer Detection

Date:

Claritas HealthTech’s subsidiary, Intelligent Scopes Corp (ISC), will take the lead in the global deployment of CystoSmart™, an AI diagnostic tool for bladder cancer detection. The technology, developed by Claritas in collaboration with Singapore’s Khoo Teck Puat Hospital (KTPH) and the National Healthcare Group’s Centre for Medical Technologies and Innovations (CMTi), aims to enhance the accuracy and efficiency of bladder cancer diagnostics.

Bladder cancer is a prevalent form of cancer, ranking as the 10th most common worldwide and the 6th most common among men. However, diagnosing the condition through cystoscopy examinations can be challenging and resource-intensive. CystoSmart™ offers a groundbreaking solution with superior detection rates and is currently undergoing FDA review for clearance.

Dr. Laszlo Neumann, CTO of Claritas, expressed excitement about working with the clinical team from Singapore to develop CystoSmart™. The joint objective has been to create a precise AI tool that can aid clinicians in significantly improving patient care.

Dr. Siying Yeow, clinical principal investigator for CystoSmart™ and consultant urologist at KTPH, has also expressed satisfaction with the progress made in developing the AI diagnostic tool. The goal has been to enhance the accuracy of bladder cancer detection and enable appropriate treatment for newly diagnosed cancers, accurate recognition of tumor recurrences, and complete tumor resection during surgery.

Claritas HealthTech is a leader in image enhancement and AI diagnostic solutions, focusing on medical image processing and AI-assisted interpretation and diagnostics. The company aims to transform the diagnostics industry by providing powerful and effective software products created using image enhancement and AI technology.

See also  Machine Learning Identifies Trauma Patients Who Benefit from Tranexamic Acid

Intelligent Scopes Corp specializes in image processing, image enhancement, AI diagnostic tools, and robotic guidance systems for endoscopy in the fields of urology and gastroenterology. Their cutting-edge solutions aim to improve detection rates, reduce unnecessary biopsies, and enhance patient outcomes.

Khoo Teck Puat Hospital (KTPH) is a 795-bed general and acute care public hospital in Singapore. As part of the National Healthcare Group (NHG), KTPH serves over 550,000 people residing in the northern sector of Singapore.

The global deployment of CystoSmart™ under the leadership of ISC highlights the significance of AI technology in revolutionizing medical diagnostics. By providing accurate and efficient detection of bladder cancer, this innovative tool has the potential to improve patient outcomes and contribute to the advancement of healthcare worldwide.

For media inquiries or further information regarding Claritas HealthTech and Intelligent Scopes Corp, please visit their respective websites.

Frequently Asked Questions (FAQs) Related to the Above News

What is CystoSmart™?

CystoSmart™ is an AI diagnostic tool developed by Claritas HealthTech's subsidiary, Intelligent Scopes Corp (ISC), in collaboration with Singapore's Khoo Teck Puat Hospital (KTPH) and the National Healthcare Group's Centre for Medical Technologies and Innovations (CMTi). It aims to enhance the accuracy and efficiency of bladder cancer diagnostics.

How common is bladder cancer?

Bladder cancer is a prevalent form of cancer, ranking as the 10th most common worldwide and the 6th most common among men.

Why is diagnosing bladder cancer challenging?

Diagnosing bladder cancer through cystoscopy examinations can be challenging and resource-intensive, often resulting in suboptimal detection rates.

How does CystoSmart™ address the challenges in diagnosing bladder cancer?

CystoSmart™ offers a groundbreaking solution with superior detection rates. It is an AI tool that aids clinicians in significantly improving patient care by providing accurate and efficient detection of bladder cancer.

Is CystoSmart™ currently available for use?

CystoSmart™ is currently undergoing FDA review for clearance.

What is the goal of developing CystoSmart™?

The goal of developing CystoSmart™ is to enhance the accuracy of bladder cancer detection, enable appropriate treatment for newly diagnosed cancers, accurately recognize tumor recurrences, and achieve complete tumor resection during surgery.

What is the role of Dr. Laszlo Neumann in the development of CystoSmart™?

Dr. Laszlo Neumann, CTO of Claritas, has expressed excitement about working with the clinical team from Singapore to develop CystoSmart™. He aims to create a precise AI tool that can aid clinicians in significantly improving patient care.

What is the role of Dr. Siying Yeow in the development of CystoSmart™?

Dr. Siying Yeow, clinical principal investigator for CystoSmart™ and consultant urologist at KTPH, has expressed satisfaction with the progress made in developing the AI diagnostic tool. Her goal is to enhance the accuracy of bladder cancer detection and enable appropriate treatment for patients.

What is the focus of Claritas HealthTech?

Claritas HealthTech is a leader in image enhancement and AI diagnostic solutions, focusing on medical image processing and AI-assisted interpretation and diagnostics.

What is the focus of Intelligent Scopes Corp?

Intelligent Scopes Corp specializes in image processing, image enhancement, AI diagnostic tools, and robotic guidance systems for endoscopy in the fields of urology and gastroenterology.

What is the significance of the global deployment of CystoSmart™?

The global deployment of CystoSmart™ under the leadership of ISC highlights the significance of AI technology in revolutionizing medical diagnostics. This innovative tool has the potential to improve patient outcomes and contribute to the advancement of healthcare worldwide.

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Share post:

Subscribe

Popular

More like this
Related

HCLTech Partners with Arm on Custom AI Silicon Chips Revolutionizing Data Centers

HCLTech partners with Arm to revolutionize data centers with custom AI chips, optimizing AI workloads for efficiency and performance.

EDA Launches Tender for Advanced UAS Integration in European Airspace

EDA launches tender for advanced UAS integration in European airspace. Enhancing operational resilience and navigation accuracy. Register now!

Ethereum ETF Approval Sparks WienerAI Frenzy for 100x Gains!

Get ready for 100x gains with WienerAI as potential Ethereum ETF approval sparks frenzy for ETH investors! Don't miss out on this opportunity.

BBVA Launches Innovative AI Program with ChatGPT to Revolutionize Business Operations

BBVA partners with OpenAI to revolutionize business operations through innovative ChatGPT AI program, enhancing productivity and innovation.